CoChat

Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic Stroke

Diener, Hans Christoph · 1998 · Cerebrovascular Diseases
Cited by 119

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Lubeluzole is a benzothiazole derivative that has shown neuroprotective properties in different experimental models. This multicentre, double-blind, placebo-controlled trial was conducted to assess the safety and efficacy of lubeluzole in patients with an acute ischaemic stroke. Methods: Patients who presented with clinical signs and symptoms of acute cerebral hemispheric ischaemic stroke were randomised to intravenous therapy with placebo (n = 360) or lubeluzole 7.5 mg over 1 h followed by 10 mg/day for up to 5 days (n = 365). Treatment was initiated within 6 h of symptom onset. Mortality at 12 weeks was the primary end point. Secondary end points included neurological status (European Stroke Scale), functional outcome (Barthel Index), and disability level (Rankin Scale). The primary and secondary end points were all analysed using the protocol-defined Cochran-Mantel-Haenszel’s general association test. An additional analysis, the logistic regression approach, that included risk factors of age, baseline stroke severity and their interactions with treatment, was used to analyze outcome measures at 3 months. Results: In the total ischaemic stroke population, the overall mortality rate at 3 months was similar for lubeluzole (21.0%) and placebo (21.4%). The logistic regression model confirmed the effect of age on mortality risk, but showed that this was independent of treatment. Treatment benefit was related to stroke severity, as determined by the Clinical Global Impression rating, that is a pronounced clinically significant reduction in mortality was noted in the lubeluzole-treated patients for whom stroke severity was mild to moderate, but not in those for whom it was severe. This was found on the basis of a post hoc analysis not specified in the hypothesis. Lubeluzole did not increase morbidity among stroke survivors, as measured by the European Stroke Scale, Barthel Index and Rankin Scale. No safety concerns were seen with lubeluzole treatment. Conclusions: In the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome. Among patients with mild to moderate ischaemic stroke, lubeluzole decreased mortality without increasing morbidity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000015847

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 119

Metadata

Authors
Diener, H. C.
Venue
Cerebrovascular Diseases
Publisher
S. Karger AG
Published
1998
Volume
8
Issue
3
Pages
172-181
ISSN
  • 1015-9770 (ISSN-L)
  • 1421-9786
OpenAlex
W2065548817
Cited by
119
References
1
FWCI
14.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic Stroke. https://app.cochat.ai/papers/10.1159/000015847
The paper
Diener, H. C. (1998). Multinational Randomised Controlled Trial of Lubeluzole in Acute Ischaemic Stroke. Cerebrovascular Diseases. https://doi.org/10.1159/000015847

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.